NEW YORK, April 30, 2013 /PRNewswire/ -- Diaceutics Limited, a leading personalized healthcare consultancy, and CAHG, a leading professional healthcare communications company, today announced a strategic partnership to develop marketing campaigns specific to personalized healthcare. This value-enhancing marketing service will enable pharmaceutical companies to comprehensively plan and execute global marketing campaigns relevant to targeted therapy and molecular diagnostics.
"The strategic alliance with Diaceutics fits with our overall goal to accelerate the adoption of personalized healthcare into clinical practice," said Scott Cotherman, President and CEO, CAHG and Chairman, TBWA\WorldHealth. "Together we can offer strategies and tactical implementation, from consulting through communication, to help clients realize the promise of personalized healthcare for all stakeholders. Our joint services will be available in the second quarter of 2013."
Diaceutics and CAHG joined forces over the last 12 months to identify clinical and communication gaps, as well as the opportunities arising in the emerging personalized healthcare field. A recently completed study with 400 physicians in the U.S. and EU conducted by CAHG and the Adelphi Group illustrates the opportunity to re-engineer the traditional approach to pharmaceutical marketing and integrate it with the value proposition of personalized healthcare to improve clinical outcomes."We are delighted to partner with CAHG, leverage their marketing expertise, and in turn help our pharmaceutical and diagnostic clients create personalized healthcare-specific brands," said Peter Keeling, CEO, Diaceutics. "Personalized healthcare marketing brings its own unique set of challenges in terms of education and multiple stakeholder involvement. However, we believe this represents a significant opportunity for our clients to take a fresh approach to pharmaceutical marketing, away from the one-size-fits-all message towards educational programs that aid the patient journey and help physicians select the tests and treatments best suited to those patients. The right treatment for the right patient begins with the right knowledge."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts